Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary empirical data
PubMed 37025099 · doi:10.2147/DHPS.S383130
What was done
This narrative review synthesized the pharmacokinetics, safety considerations, and clinical usage of oral (e.g., Andriol, Jatenzo, Tlando, Kyzatrex) and injectable (Aveed, Nebido) testosterone undecanoate products for treating testosterone deficiency (serum total testosterone < 300 ng/dL with clinical symptoms).
What was found
The abstract reports no numerical outcome data, safety statistics, or comparative effect sizes. It qualitatively describes oral testosterone undecanoate as a convenient option that may improve compliance and notes that injectable testosterone therapy is the most cost-effective option and suitable as initial therapy for most patients.
Why it matters
The paper summarizes the distinct clinical and pharmacokinetic attributes of available testosterone undecanoate options to help clinicians personalize therapy according to patient goals and cost considerations.
Limits
As a narrative review, it presents no original empirical data, sample size, or systematic methodology. No quantitative comparisons between oral and injectable formulations are reported in the abstract.
Cited by
- supports Oral formulations Tlando, Jatenzo, and Kyzatrex deliver testosterone undecanoate via lymphatic absorption without requiring 17-alpha-alkylation, avoiding the classic first-pass hepatotoxicity of older oral androgens.